Domestic pharm companies failed in patent challenges to leukemia therapy ‘Tasigna’
Domestic pharmaceutical companies challenged to a substance patent of ‘Tasigna,’ a Novartis’ chronic myelogenous leukemia therapy, but failed.
According to the industry on the 8th, Kukje Pharm and Navi Pharm applied for a nullification trial for the term extension of the Tasigna’s ‘inhibitor of ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
